COVID-19 Vaccine Makers Serum Institute of India, Bharat Biotech Targeted by Chinese Hackers: Cyfirma

Serum Institute of India, Bharat Biotech vaccines are being used in the country's immunisation campaign.

Advertisement
By Reuters | Updated: 1 March 2021 21:16 IST
Highlights
  • Serum Institute of India, Bharat Biotech are producing COVID-19 vaccines
  • The vaccines are being used for India's immunisation drive
  • Chinese hacking group APT10 (Stone Panda) said to be behind the attack

Serum Institue of India, Bharat Biotech are manufacturing Covishield and Covaxin, respectively.

Photo Credit: Reuters

A Chinese state-backed hacking group has in recent weeks targeted the IT systems of two Indian vaccine makers whose coronavirus shots are being used in the country's immunisation campaign, cyber intelligence firm Cyfirma told Reuters. India produces more than 60 percent of all vaccines sold in the world. Goldman Sachs-backed Cyfirma, based in Singapore and Tokyo, said Chinese hacking group APT10, also known as Stone Panda, had identified gaps and vulnerabilities in the IT infrastructure and supply chain software of Bharat Biotech and the Serum Institute of India (SII), the world's largest vaccine maker.

"The real motivation here is actually exfiltrating intellectual property and getting competitive advantage over Indian pharmaceutical companies," said Cyfirma Chief Executive Kumar Ritesh, formerly a top cyber official with British foreign intelligence agency MI6. He said APT10 was actively targeting SII, which is making the AstraZeneca vaccine for many countries and will soon start bulk-manufacturing Novavax shots.

"In the case of Serum Institute, they have found a number of their public servers running weak web servers, these are vulnerable web servers," Ritesh said, referring to the hackers. "They have spoken about weak web application, they are also talking about weak content-management system. It's quite alarming."

Advertisement

China's foreign ministry did not reply to a request for comment. SII and Bharat Biotech declined to comment.

Advertisement

The office of the director-general of the state-run Indian Computer Emergency Response Team (CERT) said the matter had been handed to its operations director, S.S Sarma. Sarma told Reuters CERT was a "legal agency and we can't confirm this thing to media". Cyfirma said in a statement it had informed CERT authorities and that they had acknowledged the threat. "They checked and they came back," Cyfirma said.

"Our technical analysis and evaluation verified the threats and attacks."

Advertisement

The US Department of Justice said in 2018 that APT10 had acted in association with the Chinese Ministry of State Security. Microsoft said in November that it had detected cyberattacks from Russia and North Korea targeting COVID-19 vaccine companies in India, Canada, France, South Korea, and the US.

North Korean hackers also tried to break into the systems of British drugmaker AstraZeneca, Reuters has reported. Ritesh, whose firm follows the activities of some 750 cyber criminals and monitors nearly 2,000 hacking campaigns using a tool called DeCYFIR, said it was not yet clear what vaccine-related information APT10 may have accessed from the Indian companies. Bharat Biotech's Covaxin shot, developed with the state-run Indian Council of Medical Research, will be exported to many countries, including Brazil and the US.

Advertisement

Drugmaker Pfizer Inc and its German partner BioNTech SE said in December that documents related to development of their COVID-19 vaccine had been "unlawfully accessed" in a cyberattack on Europe's medicines regulator.


Should the government explain why Chinese apps were banned? We discussed this on Orbital, our weekly technology podcast, which you can subscribe to via Apple Podcasts, Google Podcasts, or RSS, download the episode, or just hit the play button below.

Affiliate links may be automatically generated - see our ethics statement for details.
 

Get your daily dose of tech news, reviews, and insights, in under 80 characters on Gadgets 360 Turbo. Connect with fellow tech lovers on our Forum. Follow us on X, Facebook, WhatsApp, Threads and Google News for instant updates. Catch all the action on our YouTube channel.

Advertisement

Related Stories

Popular Mobile Brands
  1. Vivo X300 Could be Available in This India-Exclusive Colourway
  2. iQOO 15 Indian Variant Allegedly Surfaces on Geekbench Ahead of Launch
  3. Samsung Galaxy Book 6 Pro Allegedly Listed on Geekbench With These Specs
  4. Apple CEO Confirms Partnership Plans for AI Services Beyond OpenAI
  5. Realme GT 8 Pro Display Specifications Teased Ahead of India Launch
  6. Vivo X300 Series With 200-Megapixel Zeiss Camera Launched Globally
  7. Gemini vs Perplexity vs ChatGPT: Which Free AI Plan Is Best For You
  8. WhatsApp Will Soon Let You Reply, React to Messages Using Your Apple Watch
  9. You Can Now Repair the iPhone 17 Series, iPhone Air Yourself in These Regions
  10. Realme GT 8 Pro India Launch Date Leaked: Here's When It Might Arrive
  1. Vivo X300 to Be Available in India-Exclusive Red Colourway, Tipster Claims
  2. OpenAI Introduces Aardvark, an Agentic Security Researcher That Can Find and Fix Vulnerabilities
  3. Xiaomi 17, Poco F8 Series and Redmi Note 15 Listed on IMDA Certification Website Hinting at Imminent Global Launch
  4. CERT-In Warns Google Chrome Users of High-Risk Flaws on Windows, macOS, and Linux
  5. Kantara: A Legend Chapter 1 Now Streaming Online: Know Everything About Plot, Streaming, Cast, and More
  6. MediaTek Dimensity 8500 SoC Architecture, Specifications Leaked; Could Launch Soon
  7. Bitcoin Slips to $109,000 as Traders React to Uncertainty Over Future US Fed Rate Cuts
  8. OnePlus 15T Launch Timeline, Key Features Leaked Again; Could Feature a 7,000mAh Battery
  9. Realme GT 8 Pro Teased to Come With 2K Display and Ultra Haptics Motor Ahead of India Launch
  10. Samsung and Nvidia Partner to Build an AI Megafactory to Automate Manufacturing
Gadgets 360 is available in
Download Our Apps
Available in Hindi
© Copyright Red Pixels Ventures Limited 2025. All rights reserved.